Qube Research & Technologies LTD Biotechnology

Qube Research & Technologies LTD

$72.9 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRCA Verrica Pharmaceuticals Inc.	$327M	$280,000 0.0% of portfolio	35,262	Q4 2024 Reduced 89.06%
FHTX Foghorn Therapeutics Inc.	$177M	$234,000 0.0% of portfolio	49,643	Q4 2024 Added 141.58%
ALXO Alx Oncology Holdings Inc	$24M	$231,000 0.0% of portfolio	138,470	Q4 2024 Reduced 69.75%
BDTX Black Diamond Therapeutics, Inc.	$54.9M	$229,000 0.0% of portfolio	107,275	Q4 2024 New
AKRO Akero Therapeutics, Inc.	$1.79B	$223,000 0.0% of portfolio	8,040	Q4 2024 New
CDXS Codexis, Inc.	$146M	$216,000 0.0% of portfolio	45,348	Q4 2024 Reduced 43.02%
ATHA Athira Pharma, Inc.	$9.45M	$206,000 0.0% of portfolio	350,007	Q4 2024 Added 455.28%
VIGL Vigil Neuroscience, Inc.	$50.9M	$182,000 0.0% of portfolio	108,482	Q4 2024 Added 154.74%
ATOS Atossa Therapeutics, Inc.	$83.6M	$178,000 0.0% of portfolio	189,579	Q4 2024 Reduced 3.07%
SGMO Sangamo Therapeutics, Inc	$122M	$168,000 0.0% of portfolio	165,367	Q4 2024 New
NVCT Nuvectis Pharma, Inc.	$136M	$166,000 0.0% of portfolio	30,594	Q4 2024 Added 36.38%
CGEM Cullinan Oncology, Inc.	$382M	$165,000 0.0% of portfolio	13,609	Q4 2024 New
IMUX Immunic, Inc.	$30M	$165,000 0.0% of portfolio	165,761	Q4 2024 Reduced 5.26%
FENC Fennec Pharmaceuticals Inc.	$138M	$138,000 0.0% of portfolio	21,938	Q4 2024 Reduced 54.97%
VNDA Vanda Pharmaceuticals Inc.	$249M	$131,000 0.0% of portfolio	27,481	Q4 2024 New
ACET Adicet Bio, Inc.	$23.2M	$130,000 0.0% of portfolio	136,107	Q4 2024 Added 3.94%
ABOS Acumen Pharmaceuticals, Inc.	$41.3M	$117,000 0.0% of portfolio	68,321	Q4 2024 Reduced 17.39%
ADGI Adagio Therapeutics, Inc.	$505M	$105,000 0.0% of portfolio	31,767	Q4 2024 Reduced 80.96%
LYRA Lyra Therapeutics, Inc.	$2.86M	$71,000 0.0% of portfolio	342,159	Q4 2024 New
INMB Inmune Bio, Inc.	$148M	$62,000 0.0% of portfolio	13,298	Q4 2024 New
NKTR Nektar Therapeutics	$124M	$61,000 0.0% of portfolio	65,759	Q4 2024 New
CTMX Cytom X Therapeutics, Inc.	$49.5M	$56,000 0.0% of portfolio	55,108	Q3 2024 Added 0.92%
PLX Protalix Bio Therapeutics, Inc.	$131M	$47,000 0.0% of portfolio	24,867	Q4 2024 Reduced 31.76%
STTK Shattuck Labs, Inc.	$36.9M	$43,000 0.0% of portfolio	36,347	Q4 2024 Reduced 41.8%
TCRX T Scan Therapeutics, Inc.	$28.6M	$43,000 0.0% of portfolio	14,508	Q4 2024 Reduced 73.41%
PYXS Pyxis Oncology, Inc.	$38.6M	$38,000 0.0% of portfolio	24,524	Q4 2024 Reduced 66.35%
SEER Seer, Inc.	$122M	$38,000 0.0% of portfolio	16,610	Q4 2024 Reduced 53.05%
FGEN Fibrogen Inc	$28.1M	$18,000 0.0% of portfolio	34,976	Q4 2024 Reduced 45.82%
ELEV Elevation Oncology, Inc.	$8.62M	$14,000 0.0% of portfolio	24,217	Q4 2024 Added 128.59%
GALT Galectin Therapeutics Inc	$79.6M	$14,000 0.0% of portfolio	12,130	Q4 2024 New
ANTX An2 Therapeutics, Inc.	$25.6M	$13,000 0.0% of portfolio	10,185	Q4 2024 New
ALVR Allovir, Inc.	$913M	$6,000 0.0% of portfolio	14,539	Q4 2024 Reduced 57.66%
BLRX Bio Line Rx Ltd.	$178M	$2,000 0.0% of portfolio	11,935	Q4 2024 Reduced 8.44%
EYEN Eyenovia, Inc.	$36.3M	$1,000 0.0% of portfolio	12,227	Q4 2024 Reduced 37.14%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	130,289	Q4 2024 Added 228.22%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.